Lipigon Pharmaceuticals AB Cash Flow Conversion Efficiency
Lipigon Pharmaceuticals AB cash flow conversion efficiency. Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has a cash flow conversion efficiency ratio of -0.806x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.38 Million ≈ $-686.81K USD) by net assets (Skr7.91 Million ≈ $851.67K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lipigon Pharmaceuticals AB (2018–2025)
Cash flow conversion efficiency of Lipigon Pharmaceuticals AB from 2018 to 2025. This chart illustrates how Lipigon Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LPGO live share price for real-time trading data and today's change.
Lipigon Pharmaceuticals AB Cash Flow Conversion Ratio Explained
Lipigon Pharmaceuticals AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lipigon Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their cash flow conversion efficiency. Also see LPGO stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sancus Lending Group Ltd
LSE:LEND
|
-39.903x |
|
Predator Oil & Gas Holdings Plc
LSE:PRD
|
-0.067x |
|
OCA Acquisition Corp
NASDAQ:OCAXU
|
-0.003x |
|
Block Energy PLC
LSE:BLOE
|
0.007x |
|
Livento Group Inc.
NASDAQ:NUGND
|
0.001x |
|
AYURCANN HOLDINGS CORP.
F:3ZQ0
|
0.263x |
|
Advanced Info Service Public Company Limited
F:AISF
|
0.311x |
|
ARWAY CORP.
F:E65
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Lipigon Pharmaceuticals AB (2018–2025)
The table below shows the annual cash flow conversion efficiency of Lipigon Pharmaceuticals AB from 2018 to 2025. Review Lipigon Pharmaceuticals AB (LPGO) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr7.91 Million ≈ $851.67K |
Skr-35.77 Million ≈ $-3.85 Million |
-4.520x | -41.57% |
| 2024-12-31 | Skr7.76 Million ≈ $835.21K |
Skr-24.78 Million ≈ $-2.67 Million |
-3.193x | -534.28% |
| 2023-12-31 | Skr28.44 Million ≈ $3.06 Million |
Skr-14.32 Million ≈ $-1.54 Million |
-0.503x | +94.80% |
| 2022-12-31 | Skr3.87 Million ≈ $416.58K |
Skr-37.47 Million ≈ $-4.03 Million |
-9.679x | -529.59% |
| 2021-12-31 | Skr22.96 Million ≈ $2.47 Million |
Skr-35.30 Million ≈ $-3.80 Million |
-1.537x | -131.41% |
| 2020-12-31 | Skr12.98 Million ≈ $1.40 Million |
Skr-8.62 Million ≈ $-928.19K |
-0.664x | +74.08% |
| 2019-12-31 | Skr2.17 Million ≈ $233.42K |
Skr-5.56 Million ≈ $-598.24K |
-2.563x | -166.14% |
| 2018-12-31 | Skr-842.00K ≈ $-90.61K |
Skr-3.26 Million ≈ $-351.15K |
3.875x | -- |
About Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which… Read more